REC-4881 Cuts Polyp Burden 87% in Phase 1b/2; Recursion Extends Runway Into 2029
RXRX sits 51% above its 52-week low of $2.77 on elevated volume (3.0× avg).
Summary
Recursion reported strong Week 12 data for REC-4881 in the TUPELO Phase 1b/2 trial: an 87% mean reduction in GI polyp burden, 47% median reduction, and a 92% drop in upper GI polyps, with roughly half of patients achieving at least a 65% reduction. Responses held up at Week 25, and safety was clean — no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027 pending FDA discussions. Separately, Sanofi exercised its option on the collaboration's first development candidate, triggering an immediate $10M milestone payment. Recursion held about $561M in cash as of Sept 30, 2026, and with roughly $200M gross from the October offering, says its runway now extends into 2029. The cash cushion matters given the $200M raise priced yesterday at $3.25, a discount to the $3.74 reference price, and Q2 revenue that missed consensus by 39% on declining Roche/Genentech collaboration revenue.
At the time of this announcement, RXRX was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $2.77 to $7.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.